BioCardia, Inc. (BCDA)
BCDA moved a median of -0.06% 30 minutes after news, and -0.38% by the close. How BCDA actually reacts to news — the realized, point-in-time move the market made, measured across 356 labeled events over the last three years with zero look-ahead.
BCDA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 35% | 343 |
| 30-min | -0.06% | 44% | 354 |
| 60-min | -0.36% | 44% | 355 |
| to close | -0.38% | 44% | 352 |
| Middle 50% of BCDA reactions | -2.84% to +1.57% |
|---|---|
| Median reaction (30-min) | -0.06% |
| Measured reactions | 356 |
Half of all BioCardia, Inc. news events land between -2.84% and +1.57% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BCDA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BCDA's baseline. Nothing else.
Recent BCDA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting | Press release | GlobeNewswire | +0.00% | +1.87% | |
| Form 8-K BioCardia, Inc. For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.87% | |
| BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter | Press release | GlobeNewswire | -0.49% | +0.99% | |
| Form 8-K BioCardia, Inc. For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -0.49% | +0.99% | |
| BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission | Press release | GlobeNewswire | +1.94% | +1.94% | |
| Form 8-K BioCardia, Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +1.94% | +1.94% | |
| Form 8-K BioCardia, Inc. For: Sep 21 | SEC filing · Form 8-K | SEC EDGAR | +0.97% | +1.94% | |
| BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +0.00% | +0.92% | |
| Form 8-K BioCardia, Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.92% | |
| BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval | Press release | GlobeNewswire | +0.01% | +6.01% | |
| Form 8-K BioCardia, Inc. For: Aug 24 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | +6.01% | |
| Form 8-K BioCardia, Inc. For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | +6.01% | |
| BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results | Press release | GlobeNewswire | +3.53% | +5.56% | |
| Form 10-Q BioCardia, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.53% | +5.56% | |
| Form 8-K BioCardia, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +3.53% | +5.56% | |
| BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026 | Press release | GlobeNewswire | -0.82% | -1.84% | |
| BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities | Press release | GlobeNewswire | -0.20% | -2.28% | |
| Form 8-K BioCardia, Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -0.20% | -2.28% | |
| Form 8-K BioCardia, Inc. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +10.00% | |
| BioCardia Announces $4.4 Million Financing | Press release | GlobeNewswire | -6.66% | -10.68% | |
| Form 8-K BioCardia, Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -6.66% | -10.68% | |
| FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF | Press release | GlobeNewswire | -4.17% | -14.17% | |
| Form 8-K BioCardia, Inc. For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | -4.17% | -14.17% | |
| BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure | Press release | GlobeNewswire | +0.00% | -1.42% | |
| Form 8-K BioCardia, Inc. For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.42% | |
| BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency | Press release | GlobeNewswire | +2.69% | -1.45% | |
| Form 8-K BioCardia, Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +2.69% | -1.45% | |
| BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase | Press release | GlobeNewswire | -1.09% | +3.36% | |
| BioCardia Reports First Quarter 2026 Business Highlights and Financial Results | Press release | GlobeNewswire | -1.81% | -8.18% | |
| Form 10-Q BioCardia, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.81% | -8.18% | |
| Form 8-K BioCardia, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -1.81% | -8.18% | |
| BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026 | Press release | GlobeNewswire | — | +1.82% | |
| BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways | Press release | GlobeNewswire | -4.44% | -0.89% | |
| Form 8-K BioCardia, Inc. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -4.44% | -0.89% | |
| BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures | Press release | GlobeNewswire | +0.00% | -0.87% | |
| Form 8-K BioCardia, Inc. For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.87% | |
| BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure | Press release | GlobeNewswire | -0.42% | +4.17% | |
| Form 8-K BioCardia, Inc. For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | +4.17% | |
| Form 8-K BioCardia, Inc. For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.85% | |
| BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure | Press release | GlobeNewswire | -2.54% | +1.70% | |
| Form 8-K BioCardia, Inc. For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| BioCardia Reports 2025 Business Highlights and Financial Results | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 10-K BioCardia, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K BioCardia, Inc. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form S-8 BioCardia, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +0.00% | |
| BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 | Press release | GlobeNewswire | — | +0.84% | |
| BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA | Press release | GlobeNewswire | -0.78% | +0.00% | |
| Form 8-K BioCardia, Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -0.78% | +0.00% | |
| BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT) | Press release | GlobeNewswire | -2.46% | -4.50% | |
| Form 8-K BioCardia, Inc. For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -2.46% | -4.50% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BCDA section they belong to.
Where else BCDA is measured.
BCDA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AQUINOX PHARMACEUTICALS (AQXP) | 357 | 0.00% | 46% |
| Hologic, Inc. (HOLX) | 357 | -0.00% | 44% |
| BioMarin Pharmaceutical Inc. (BMRN) | 356 | -0.08% | 45% |
| McKesson Corporation (MCK) | 355 | +0.02% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BioCardia, Inc.'s median reaction calculated?
Every labeled BCDA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 356 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of BCDA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BCDA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.